NextCell Pharma
1.30 SEK
+1.25 %
Less than 1K followers
NXTCL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for NextCell Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 1.8 | 3.6 | 3.9 | 5.6 | 10.1 | 10.7 | 10.9 |
| growth-% | 96.7 % | 9.8 % | 42.9 % | 80.9 % | 5.4 % | 2.6 % | |
| EBITDA | -21.1 | -17.3 | -24.4 | -34.6 | -40.8 | -42.2 | -33.4 |
| EBIT | -21.5 | -17.7 | -24.8 | -35.0 | -41.0 | -43.2 | -35.9 |
| Profit before taxes | -21.5 | -17.7 | -24.6 | -34.6 | -39.8 | -42.0 | -35.1 |
| Net income | -21.5 | -17.7 | -24.6 | -34.6 | -39.8 | -42.0 | -35.1 |
| EPS | -0.91 | -0.65 | -0.83 | -0.80 | -0.92 | -1.03 | -0.44 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -1,164.7 % | -485.5 % | -623.3 % | -618.4 % | -403.6 % | -395.9 % | -305.0 % |
| EBIT-% | -1,183.9 % | -496.7 % | -634.5 % | -626.5 % | -405.5 % | -405.0 % | -328.0 % |
| ROE | -93.4 % | -67.4 % | -16.4 % | -29.9 % | -52.6 % | -62.1 % | -52.9 % |
| ROI | -80.3 % | -59.4 % | -15.8 % | -27.7 % | -44.8 % | -51.6 % | -45.8 % |